Use of Paclitaxel-Coated Balloons in the United States: Early Results From the AGENT Postapproval Study
Circulation: Cardiovascular Interventions · 2026-08 · 19 (8)
DOI: 10.1161/circinterventions.126.016625 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Circulation: Cardiovascular Interventions, 2026-08. Verfasst von Christina Lalani und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston MA (C.L., E.S., R.W.Y.). Hauptthemen laut MEDLINE: Paclitaxel, Angioplasty, Balloon, Coronary, Cardiovascular Agents, Coronary Restenosis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.
Abstract (Originalsprache)
BACKGROUND: AGENT is the only coronary drug-coated balloon (DCB) approved for treatment of in-stent restenosis (ISR) in the United States to date. In this study, we describe trends in DCB use and compare characteristics and in-hospital outcomes between patients who received DCB versus alternative treatments. METHODS: We included patients in the American College of Cardiology National Cardiovascular Disease Registry CathPCI Registry who underwent percutaneous coronary intervention between April 2024 and June 2025 and received DCB, drug-eluting stent (DES), or plain old balloon angioplasty. Treatment groups were compared using standard mean differences. RESULTS: Between April 2024 and June 2025, 14 946 DCBs were used in 12 337 patients across 704 CathPCI Registry sites. The monthly rate of DCB use for ISR percutaneous coronary intervention grew from
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston MA (C.L., E.S., R.W.Y.).
- Richard A. and Susan F. Smith Center for Outcomes Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA (C.L., E.S., Y.S., H.D., R.W.Y.).
- Columbia University Irving Medical Center/New York-Presbyterian Hospital (A.J.K.).
- Cardiovascular Research Foundation, New York, NY (A.J.K.).
- Banner University Medical Center, Phoenix, AZ (S.N.).
- Cleveland Clinic Foundation, OH (A.K.).
ORCID-Profile: Christina Lalani, Eric A Secemsky, Yang Song, Ajay J Kirtane, Amar Krishnaswamy, Matthew J Price, Rhian E Davies, Kathleen E Kearney, Ziad A Ali, Robert W Yeh
Förderung
- NHLBI NIH HHS
Zitieren
APA
Lalani, C., Secemsky, E. A., Song, Y., Dong, H., Kirtane, A. J., Neupane, S., Krishnaswamy, A., Price, M. J., Davies, R. E., Frizzell, J. D., Kearney, K. E., Safirstein, J. G., Ali, Z. A., Cavalcante, R., & Yeh, R. W. (2026). Use of Paclitaxel-Coated Balloons in the United States: Early Results From the AGENT Postapproval Study. Circulation: Cardiovascular Interventions, 19(8). https://doi.org/10.1161/circinterventions.126.016625
Vancouver
Lalani C, Secemsky EA, Song Y, Dong H, Kirtane AJ, Neupane S, et al. Use of Paclitaxel-Coated Balloons in the United States: Early Results From the AGENT Postapproval Study. Circulation: Cardiovascular Interventions. 2026;19(8). doi:10.1161/circinterventions.126.016625
BibTeX
@article{Lalani2026,
author = {Lalani, Christina and Secemsky, Eric A and Song, Yang and Dong, Huaying and Kirtane, Ajay J and Neupane, Saroj and Krishnaswamy, Amar and Price, Matthew J and Davies, Rhian E and Frizzell, Jarrod D and Kearney, Kathleen E and Safirstein, Jordan G and Ali, Ziad A and Cavalcante, Rafael and Yeh, Robert W},
title = {Use of Paclitaxel-Coated Balloons in the United States: Early Results From the AGENT Postapproval Study},
journal = {Circulation: Cardiovascular Interventions},
year = {2026},
volume = {19},
number = {8},
doi = {10.1161/circinterventions.126.016625}
}
EUVIMED